AUSTIN, June 8, 2015 / PRNewswire - iReach / -- Neogenis Labs, Inc today announces that Neo40 Professional, a patented and clinically proven nitric oxide technology to support healthy circulation, will begin distribution with MDgenesis LLC, a supplier of integrative medical products to Orthopedic Surgeons. As a part of the agreement, Neo40 Professional will be incorporated into the pre and post-surgery and tissue repair protocols on their patient portal MDgenesis.com. MDgenesis will also be introducing Neo40 Professional to 300+ orthopedic surgeons throughout the Western states region and within the state of California.
Neo40 Professional was selected by MDgenesis LLC after reviewing numerous nitric oxide products available on the market. Nitric oxide or NO is one of the most important molecules produced in the human body and it is critically important for wound healing and tissue repair. "We considered developing our own nitric oxide product like many other companies do, but we quickly realized Neogenis patented technology is the only technology in the world that generates authentic NO gas when taken and we knew we could not compete with that” says Ken Roycroft, chief executive officer of the company. "nitric oxide signals stem cell mobilization and is the signal that allows for wound healing and regenerative medicine. We are very pleased to incorporate Neo40 Professional into our overall surgery program for our physicians and their patients."
Building from Nobel prize-winning nitric oxide research studies, Dr. Nathan Bryan of the UT Health Science Center developed a breakthrough, N-O producing supplement. From this foundation, Neogenis Labs, has developed a platform of solutions tailored for both the home nutrition and pharmaceutical markets. The orally disintegrating lozenge, Neo40 is unique, innovative, safe and very efficacious. Proven through numerous clinical studies, the Neogenis team is now poised to deliver key innovations to the healthcare industry, providing relief to millions suffering from N-O deficiency.
"Establishment of a distribution agreement with MDgenesis is a key step in our efforts to educate both physicians and patients on the importance of nitric oxide in health and regenerative medicine," says co-founder and Chief Science Officer Nathan S. Bryan, Ph.D., "the Physicians and Surgeons have seen the overwhelmingly positive feedback and response from patients and beginning to understand that patients see the impact of nitric oxide as a critical part of their recovery program.”
Neogenis Medical is the world leader in nitric oxide science with over 15 years of research, 4 issued patents and 5 published clinical trials. Neo40® Professional is clinically shown to increase N-O levels, which is essential for proper endothelial function and cardiovascular health.
Neogenis has been named to the 2015 Austin A-List by the Austin Chamber of Commerce through its Innovate Austin initiative and South by Southwest Interactive. The A-List companies, selected by a panel of independent judges from more than 275 nominations, were officially revealed and named to the annual Austin A-List of Hottest Startups.